COMPASS Pathways launches phase II clinical trial of psilocybin therapy in anorexia nervosa Psychedelics Investing
Gwella Mushrooms CEO Peter Reitano: Early Stage Traction, Revenue and a Great Path to Profitability Psychedelics Investing
Awakn Life Sciences' Phase III Trial Approved for Approximately CA$2.5 Million Funding from UK State Covering 66% of Costs Company News
Lobe Sciences Files Patent Application Covering the Preparation of Stable Psilocin Prodrugs and Analogues and their Uses Further Strengthening its Intellectual Property Portfolio Pharmaceutical Investing
Seelos Therapeutics Doses First Patient in an Open Label Basket Study of SLS-005 in Amyotrophic Lateral Sclerosis in Australia and Provides an Enrollment Update of its Study on the HEALEY ALS Platform Psychedelics Investing
Optimi Health Finalizes Psilocybin Supply Agreement With Bloom Psychedelic Therapy And Research Centre Company News
Silo Wellness Organizes Jamaican Psilocybin Retreat Team and Advocates to Speak to Lane County Commissioners Regarding BM109 Optout Vote; Lane County Declines to Refer a Psilocybin Ban to Voters Psychedelics Investing
